Nurix (NRIX) legal chief sells 8,148 shares under 10b5-1 plan

Rhea-AI Filing Summary

Nurix Therapeutics Chief Legal Officer Christine Ring sold 8,148 shares of common stock in an open-market transaction. The weighted average sale price was $15.2367 per share, with individual trades ranging from $15.00 to $15.43. Following the sale, she directly holds 26,453 Nurix shares. The transaction was executed under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than a discretionary trade.

Insights

Equity analyst

Pre-planned insider sale of 8,148 Nurix shares looks routine.

Chief Legal Officer Christine Ring completed an open-market sale of 8,148 Nurix Therapeutics common shares at a weighted average of $15.2367 per share. The filing shows she continues to hold 26,453 shares directly after the transaction.

The sale was carried out under a previously adopted Rule 10b5-1 trading plan, which means the timing was pre-scheduled rather than opportunistic. This generally reduces the informational value of the trade for assessing management’s view of the stock.

There are no derivative transactions or option exercises reported in this filing, and no remaining derivative positions are listed. Subsequent filings may provide additional context if further planned sales occur under the same Rule 10b5-1 plan.

Insider Trade Summary 10b5-1

Net Seller: 8,148 shares ($124,149)

Net Sell 1 txn

Insider Ring Christine

Role Chief Legal Officer

Sold 8,148 shs ($124K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,148	$15.2367	$124K

Holdings After Transaction: Common Stock — 26,453 shares (Direct)

Footnotes (1)

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $15.00 and the highest price at which shares were sold was $15.43. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Key Figures

Shares sold: 8,148 shares Weighted average sale price: $15.2367 per share Post-transaction holdings: 26,453 shares +2 more

5 metrics

Shares sold 8,148 shares Open-market sale of Nurix Therapeutics common stock

Weighted average sale price $15.2367 per share Average price for 8,148 shares sold

Post-transaction holdings 26,453 shares Direct ownership after reported sale

Sale price range $15.00–$15.43 per share Lowest and highest prices for shares sold

Net share change -8,148 shares Net-sell direction in transaction summary

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, non-derivative

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which shares were sold was $15.00 and the highest price at which shares were sold was $15.43."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"transaction_type: non-derivative"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/02/2026		S(1)		8,148	D	$15.2367(2)	26,453	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $15.00 and the highest price at which shares were sold was $15.43. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

How many Nurix Therapeutics (NRIX) shares did the insider sell?

Christine Ring sold 8,148 shares of Nurix Therapeutics common stock. The sale was reported as an open-market transaction, with a weighted average price of $15.2367 per share and individual trade prices ranging from $15.00 to $15.43.

Who is the insider involved in this Nurix Therapeutics (NRIX) Form 4 filing?

The insider is Christine Ring, Chief Legal Officer of Nurix Therapeutics. She executed an open-market sale of 8,148 common shares and, after the transaction, directly holds 26,453 Nurix Therapeutics shares according to the Form 4 filing data provided.

At what prices were the Nurix (NRIX) shares sold in this insider trade?

The 8,148 Nurix Therapeutics shares were sold at a weighted average price of $15.2367. Individual trades occurred between $15.00 and $15.43 per share, as disclosed, with the insider offering to provide full price breakdowns upon request to regulators or shareholders.

How many Nurix Therapeutics (NRIX) shares does the insider still own after the sale?

After selling 8,148 shares, Christine Ring directly owns 26,453 Nurix Therapeutics common shares. This post-transaction holding figure comes from the Form 4 and reflects only her direct ownership position reported in this specific filing instance.

Was the Nurix (NRIX) insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnotes state the transaction was effected under a previously adopted Rule 10b5-1 trading plan. Such plans pre-schedule trades, which typically makes the timing less indicative of the insider’s short-term view of the stock.

Does the Nurix Therapeutics (NRIX) Form 4 include any option exercises or derivatives?

No. The reported activity is a single non-derivative common stock sale of 8,148 shares. The derivativeSummary section is empty, indicating no option exercises, warrant conversions, or other derivative transactions were disclosed in this particular Form 4 filing.